The impact of sublingual latanoprost on reducing intraocular pressure.

Ocular hypotensive effects of topical versus sublingual latanoprost: a crossover study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241015063374N1

Enrollment

Registered

2024-11-09

Start date

2024-11-20

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma. Glaucoma

Interventions

Intervention 1: Intervention group: Sublingual latanoprost 100 mcg daily for 16 weeks. Intervention 2: Intervention group: Topical latanoprost 0.005% once daily for 16 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Ocular Hypertension Early stage primary open angle glaucoma

Exclusion criteria

Exclusion criteria: Age under 18 years Age over 80 years Angle closure glaucoma Advanced open angle glaucoma History of glaucoma surgery History of any intraocular surgery except cataract surgery Secondary glaucoma History of abnormal uterine bleeding

Design outcomes

Primary

Measure	Time frame
Intraocular Pressure (IOP). Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: IOP will be measured using a goldman tonometer during each visit.	—

Secondary

Measure	Time frame
Intraocular Pressure (IOP) in the contralateral eye. Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: IOP in the contralateral eye will be measured using a tonometer.;Local adverse effects (e.g., conjunctival hyperemia, iris pigmentation, eyelash growth). Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: Local adverse effects will be assessed using a questionnaire and clinical examination during each visit.;Systemic adverse effects. Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: Systemic adverse effects will be assessed using a questionnaire and clinical examination during each visit.	—

Measure

Time frame

Intraocular Pressure (IOP) in the contralateral eye. Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: IOP in the contralateral eye will be measured using a tonometer.;Local adverse effects (e.g., conjunctival hyperemia, iris pigmentation, eyelash growth). Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: Local adverse effects will be assessed using a questionnaire and clinical examination during each visit.;Systemic adverse effects. Timepoint: Baseline (before intervention), 6 weeks after starting sublingual latanoprost, 16 weeks after switching to topical latanoprost. Method of measurement: Systemic adverse effects will be assessed using a questionnaire and clinical examination during each visit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Morteza Hosseini Imeni

Shahid Beheshti University of Medical Sciences

Mortezahosseinimd@gmail.com+98 21 6691 8271

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026